Browse

Leqembi, the anti-amyloid Alzheimer’s drug co-developed by Eisai and Biogen, generated $184 million in global sales in the second quarter, according to Biogen. The Q2 figure represents the stronge…

In a decade of leading and building Recursion Pharmaceuticals, Chris Gibson attempted to bridge the worlds of biology and technology. Now, months after leaving Recursion, he's joining a VC firm tha…